Lenvatinib Monotherapy Versus Lenvatinib in Combination with PD-1 Blockades as Re-Challenging Treatment for Patients with Metastatic Osteosarcoma: A Real-World Study
Our data indicated that patients with metastatic osteosarcoma could potentially benefit from lenvatinib rechallenge after progress with initial TKI treatment. The combination of lenvatinib and PD-1 blockade therapy demonstrated promising survival outcomes in patients with metastatic osteosarcoma, accompanied by a manageable toxicity profile.
Authors
- Huaiyuan Xu (ORCID: https://orcid.org/0000-0002-2501-4527)
- Xiaojun Zhu
- Chuangzhong Deng (ORCID: https://orcid.org/0000-0001-7697-087X)
- Jinchang Lu
- Qinglian Tang (ORCID: https://orcid.org/0000-0003-0118-0739)
- Jin Wang (ORCID: https://orcid.org/0000-0003-3625-7919)
- Anqi Wang (ORCID: https://orcid.org/0000-0002-3369-1499)
- Hao Wu (ORCID: https://orcid.org/0000-0001-8448-5284)
- Guohui Song
- Jinxin Hu
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2025-02-01
- DOI
- https://doi.org/10.2147/dddt.s501742
- Citations
- 3
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.56